ArticleBlood2018
Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
Abstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed.
- Trial
- Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2019Trial
- Article
- Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.British journal of haematology · 2026Article
- Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma.Hematological oncology · 2026Article
- Adult T-cell leukemia/lymphoma in French Guiana (1990-2019): Epidemiology, clinical features, and HTLV-1 genetic diversity in the two main ethnic populations.International journal of cancer · 2026Article
- From Genomic and Epigenomic Maps to Medicines in Adult T-Cell Leukemia/Lymphoma.Cancer science · 2026Review
- Adult T-cell leukemia/lymphoma: molecular pathogenesis, emerging therapies, and future directions.Frontiers in oncology · 2026Review
- T-cell lymphoma-associated STAT3 variants impose a type 1 regulatory-like phenotype.Frontiers in immunology · 2026Article
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Penetrant PKCβ mutation in ATLL displays a mixed gain-of-function.The Biochemical journal · 2025Article
- Epidemiology of mature T-cell and NK-cell neoplasms: east and west.The Lancet regional health. Western Pacific · 2025Review
- Article
- TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma.Leukemia · 2025Article
- Pure Red Cell Aplasia in a Patient with Thymic Hyperplasia, Hypogammaglobulinemia and Adult T-cell Leukemia/Lymphoma.Internal medicine (Tokyo, Japan) · 2025Article
- Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas.JMA journal · 2025Review
- Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations.Haematologica · 2024Article
- Deciphering the molecular landscape: evolutionary progression from gynecomastia to aggressive male breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Long-Term Survival of Patients with Adult T-Cell Leukemia/Lymphoma Treated with Amplified Natural Killer Cell Therapy.Reports (MDPI) · 2024Article
- Flow cytometric profiles with CD7 and CADM1 in CD4+ T cells are promising indicators for prognosis of aggressive ATL.Blood advances · 2024Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
43 authors.
Keisuke KataokaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-8263-9902
Masako IwanagaDepartment of Frontier Life Science, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan.
Jun-Ichirou YasunagaLaboratory of Virus Control, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Yasunobu NagataDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akira KitanakaDepartment of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.
Takuro KamedaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Makoto YoshimitsuDepartment of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.
Yuichi ShiraishiLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Aiko Sato-OtsuboDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Masashi SanadaDepartment of Advanced Diagnosis, Clinical Research Center, Nagoya Medical Center, Nagoya, Japan.
Kenichi ChibaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroko TanakaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yotaro OchiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kosuke AokiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiromichi SuzukiDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yusuke ShiozawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tetsuichi YoshizatoDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yusuke SatoDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kenichi YoshidaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kisato NosakaDepartment of Hematology, Kumamoto University School of Medicine, Kumamoto, Japan.
Masakatsu HishizawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hidehiro ItonagaDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Yoshitaka ImaizumiDepartment of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kotaro ShideDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Yoko KubukiDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tomonori HidakaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Tsuyoshi NakamakiDivision of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Ken IshiyamaDepartment of Hematology and Oncology, Kanazawa University Hospital, Kanazawa, Japan.
Shuichi MiyawakiDivision of Hematology, Department of Internal Medicine, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Ryohei IshiiDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan.
Osamu NurekiDepartment of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo, Japan.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tatsuhiro ShibataLaboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kenji IshitsukaDepartment of Hematology and Immunology, Kagoshima University Hospital, Kagoshima, Japan.
Atae UtsunomiyaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan; and.
Kazuya ShimodaDepartment of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Masao MatsuokaLaboratory of Virus Control, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.
Toshiki WatanabeDepartment of Advanced Medical Innovation, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult T-cell leukemia/lymphoma (ATL) is a heterogeneous group of peripheral T-cell malignancies characterized by human T-cell leukemia virus type-1 infection, whose genetic profile has recently been fully investigated. However, it is still poorly understood how these alterations affect clinical features and prognosis. We investigated the effects of genetic alterations commonly found in ATL on disease phenotypes and clinical outcomes, based on genotyping data obtained from 414 and 463 ATL patients using targeted-capture sequencing and single nucleotide polymorphism array karyotyping, respectively. Aggressive (acute/lymphoma) subtypes were associated with an increased burden of genetic and epigenetic alterations, higher frequencies of
Indexed as
Gene Expression Regulation, LeukemicMutationAbnormal KaryotypeAgedEpigenesis, GeneticFemaleGene DosageHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsLeukemia-Lymphoma, Adult T-CellMaleMiddle AgedModels, MolecularPolymorphism, Single NucleotidePrognosisInterferon Regulatory Factor-4Interferon Regulatory FactorsSTAT3 protein, humanSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.